SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
lj
Lv1
30 积分
2023-08-22 加入
最近求助
最近应助
互助留言
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
7天前
已完结
Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021
8天前
已完结
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
23天前
已完结
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
6个月前
已完结
1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial
9个月前
已完结
A phase Ia/Ib study of novel anti‐ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer
1年前
已完结
Mechanisms of HDAC inhibitor-induced thrombocytopenia
1年前
已完结
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
1年前
已完结
没有进行任何应助
感谢,速度真快,帮大忙了,么么哒
7天前
感谢
9个月前
非常感谢
1年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论